Home

Articles from MEI Pharma

MEI Pharma Recommends Stockholders Not to Consent
MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that it has filed a definitive consent revocation statement with the U.S. Securities and Exchange Commission (“SEC”) on October 17, 2023 in connection with the consent solicitation initiated by Anson Advisors and Cable Car Capital to remove the entire MEI Board of Directors.
By MEI Pharma · Via Business Wire · October 17, 2023